Navigation Links
National Childrens Study Begins Recruiting
Date:1/16/2009

Effort will track development of 100,000 kids from birth to age 21

FRIDAY, Jan. 16 (HealthDay News) -- Recruiting has started for a large-scale federal study that aims to track tens of thousands of children from before birth to age 21. The study is aimed at understanding of how genes and environment interact to affect health.

The National Children's Study, authorized by Congress in 2000, is expected to uncover important health information at virtually every phase of a child's life. Volunteer participants are being sought first in Duplin County, N.C., and Queens, N.Y. Recruitment will eventually expand to include 105 U.S. locations, providing a broad, representative sample of the nation's population.

"Initially, it will provide major insights into disorders of birth and infancy, such as preterm birth and its health consequences. Ultimately, it will lead to a greater understanding of adult disorders, many of which are thought to be heavily influenced by early life exposures and events," Dr. Duane Alexander, director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, said in a news release issued by the U.S. National Institutes of Health.

A consortium of federal agencies is working on the study, which hopes to track more than 100,000 children over the years.

Unlike smaller and more limited studies, Alexander said, the scope of the National Children's Study should allow researchers to gain insight into many uncommon disorders and to examine the interaction of genetics and the environment, as well.

Centers in communities where volunteers are being recruited will hold presentations and other activities to better inform prospective participants. Prenatal care providers and clinics in those areas will also inform women about the study, and some families will receive letters explaining the study.

Among the first to be enrolled in the study will b
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Tampa is Latest Recipient of Project Lifesaver Grant Funds Through The National Autism Association
2. Feeding America, Martin Luther King III, David Arquette, Josh Groban and Herbie Hancock Join Forces to Combat Hunger in America on Presidential Inaugural Committee National Day of Service
3. Arizona State University Nursing and Idea Crossing Partner to Conduct First National Healthcare Innovation Challenge
4. EBG Advisors and Oldaker Group Form National Health Advisors
5. Gift of Life Celebrates 35th Anniversary as National Leader in Organ Donation
6. Give an Hour Calls on Mental Health Professionals to Volunteer Counseling to Returning Troops as Part of President-elect Obamas National Day of Service
7. Video: Supermodel Kim Alexis Joins Forces with the American Association of Clinical Endocrinologists in a National PSA to Raise Awareness About Thyroid Problems
8. Preventing the Next Virginia Tech -- The National Behavioral Intervention Team Association Launched Today
9. AVG Anti-Virus and Walling Data Streamline Network Security for National Medical Supply Company
10. National Council of Legislators From Gaming States Adopts Resolution Supporting 100% Smokefree Gaming Venues
11. AUDIO from Medialink and the National Meningitis Association: Peak Season for Meningitis
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
National Childrens Study Begins Recruiting
National Childrens Study Begins Recruiting
(Date:12/6/2009)... College of Wisconsin, in Milwaukee, found a substantial variation ... disease complications in children. Barriers to its use on ... identified. The study led by Amanda M. Brandow, ... College and Children,s Research Institute at the Children,s Hospital ... of Hematology meeting Dec. 7, 2009, in New Orleans. ...
(Date:12/6/2009)... 2009 A new study provides welcome news for ... thromboembolism (VTE). , The condition is estimated to ... occurs when an abnormal clot forms in a vein ... swelling. In some cases, the clot may detach from ... to the lungs, causing a potentially fatal condition known ...
(Date:12/5/2009)... three-drug combination has shown in a phase 1/2 ... in the treatment of patients newly diagnosed with multiple ... marrow, say researchers from Dana-Farber Cancer Institute. , Partial ... 66 patients treated with the drug combination in the ... partial response rate" in the phase 2 population, reports ...
(Date:12/5/2009)... --In Youngest Babies, This Type of Blood Cancer Is ... Dec. 5 Pediatric oncologists have identified specific genes, ... drive an often-fatal form of leukemia in infants. By ... better predict which infants may benefit from particular treatments. ...
(Date:12/5/2009)... Technology Center helps companies develop and test their cleaning processes. The ... variety of industries and solve problems for customers relating to cleaning ... ... 5, 2009 -- Midbrook, Inc , a Jackson, MI-based company, ...
Breaking Medicine News(10 mins):Health News:New study finds barriers to pain treatment in children with sickle cell disease 2Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3
... healthcare real estate company providing ... hospitals and physicians ... CHARLOTTE, N.C., Jan. 23 Cogdell Spencer Inc.,(NYSE: ... agreement,to acquire 100 percent of the stock of Marshall Erdman ...
... [Brown University] When faced with even a ... fewer women receive these potentially life-saving breast cancer ... University and Harvard Medical School researchers. , In ... insurance co-payments and mammography rates, researchers found that ...
... 23 Pennsylvania,AFL-CIO President William George and Secretary ... decisions by,Representatives John Peterson, Joseph Pitts, and William ... millions of children in,families hit hardest by our ... in the face of a severe economic downturn,Representatives ...
... Jan. 23 Johnson & Johnson,Pharmaceutical Research & ... Drug Application (NDA) to the U.S. Food and ... an investigational oral analgesic for the relief of ... American Pain Foundation, more than 25 million,Americans experience ...
... Jan. 23 Boston Scientific (NYSE: BSX ),today ... Chief,Medical and Scientific Officer, on an article in the ... and Drug-Eluting Stents for,Off-Label Indications.", "The analysis from ... in today,s New England Journal of Medicine is the ...
... went five years without anti-rejection drugs , , WEDNESDAY, ... transplant recipients to stop taking powerful immunosuppressive drugs are ... in the development of the transplant field is to ... the lifesaving benefit of the transplant without the costs ...
Other Medicine News:Health News:Cogdell Spencer Inc. Announces Merger with Marshall Erdman and Associates 2Health News:Cogdell Spencer Inc. Announces Merger with Marshall Erdman and Associates 3Health News:Cogdell Spencer Inc. Announces Merger with Marshall Erdman and Associates 4Health News:Cogdell Spencer Inc. Announces Merger with Marshall Erdman and Associates 5Health News:Health insurance co-payments deter mammography use 2Health News:Health insurance co-payments deter mammography use 3Health News:Pennsylvania AFL-CIO Decries Shameful Votes Again by Representatives John Peterson, Joe Pitts and Bill Shuster, Against Children's Health Care 2Health News:New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets 2Health News:New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets 3Health News:New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets 4Health News:Boston Scientific Comments on New England Journal of Medicine Article 2Health News:Boston Scientific Comments on New England Journal of Medicine Article 3Health News:New Therapies Could Change Organ Transplants 2Health News:New Therapies Could Change Organ Transplants 3
(Date:12/4/2009)... N.Y., Dec. 4 Bayer Diabetes Care today announced the ... Creativity Contest." Nick Jonas, of the Jonas Brothers, selected the ... the country. The grand prize is an in-person meeting today ... 1 diabetes like Nick, are: Caleb, age 6, from Danbury, ...
(Date:12/4/2009)... AZN ) today announced that the US Food ... (quetiapine fumarate) Extended Release Tablets as adjunctive (add-on) treatment ... SEROQUEL XR is the only medication in its class ... disorder as adjunctive therapy and acute depressive episodes associated ...
(Date:12/3/2009)... Mass., Dec. 3 Allen Medical Systems, a subsidiary ... today announced the launch of its new Allen Amatech(TM) ... . ,, The website reinforces the Allen ... the new product catalog, with detailed descriptions and design ...
Breaking Medicine Technology:Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 2Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Allen Medical Systems Announces the Launch of New Allen Amatech(TM) OEM Website 2By 2018 GlaxoSmithKlines Votrient Will Garner Sales of 24640 Million and Will Overtake Pfizers Sutent as the Renal Cell Carcinoma Market Leader 57010 1By 2018 GlaxoSmithKlines Votrient Will Garner Sales of 24640 Million and Will Overtake Pfizers Sutent as the Renal Cell Carcinoma Market Leader 57010 2Caliper Life Sciences Launches IVIS 28R 29 In Vivo Imaging System with X Ray 14013 1Caliper Life Sciences Launches IVIS 28R 29 In Vivo Imaging System with X Ray 14013 2Caliper Life Sciences Launches IVIS 28R 29 In Vivo Imaging System with X Ray 14013 3Alexza Announces Preliminary Results from its AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2b Trial in Patients with Migraine Headache 4993 1Alexza Announces Preliminary Results from its AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2b Trial in Patients with Migraine Headache 4993 2Alexza Announces Preliminary Results from its AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2b Trial in Patients with Migraine Headache 4993 3Alexza Announces Preliminary Results from its AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2b Trial in Patients with Migraine Headache 4993 4Alexza Announces Preliminary Results from its AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2b Trial in Patients with Migraine Headache 4993 5
... Sanofi-aventis,announced that the U.S. Food and Drug ... in combination with cisplatin,and 5-fluorouracil for induction ... the head and neck (SCCHN) before patients ... its approval on the results of the ...
... AppyScore(TM), the First Blood-based Screen / Triage Test for Human,Appendicitis, ... ... Sensitivity Level of 98%., CASTLE ROCK, Colo., Sept. ... bio-pharmaceutical company dedicated to the,development of novel drugs and diagnostics ...
Other Medicine Technology:Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery 2Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery 3Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery 4AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study 2AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study 3AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study 4AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study 5AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study 6AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study 7AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study 8AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study 9
... volume Finnpipette Techpette combines form ... performance pipette. Advanced pipetting technology, ... ensures quality, safety, comfort and ... volume range is an important ...
Inquire...
... of moderate viscosity and density. Proven ergonomic design reduces hand fatigue, prevents ... Range (ul) ... 1.0~1.5 Imprecision(%) ... 10 Dimensions: ...
... from Thermo Labsystems was designed specifically to ... features such as the new fast dial ... microvolumes help to define this as a ... new interchangeable handle plate offers a custom ...
Medicine Products: